U.S. markets close in 2 hours 45 minutes

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5200-0.1200 (-4.55%)
As of 01:06PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close2.6400
Bid2.5100 x 1200
Ask2.5300 x 1200
Day's Range2.5100 - 2.6500
52 Week Range0.7760 - 5.6860
Avg. Volume360,954
Market Cap111.394M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-1.2730
Earnings DateNov 03, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.30
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IFRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • InflaRx N.V.
    Daily – Vickers Top Buyers & Sellers for 10/06/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

    Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patientsEUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The Lancet Respiratory MedicineRequest for EUA follows encouraging interactions with FDA in Type B meeting“Gohibic” conditionally accepted by FDA as proprietary name for vilobelimab JENA, Germany, Sept. 29, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical

  • GlobeNewswire

    InflaRx to Present at Upcoming Scientific and Investor Conferences

    JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several conferences. H.C. Wainwright 24th Annual Global Investment Conference, New York, NY USA: Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will provide a general corporate overview and update on Wednesday, September 14th at 9:30 am

  • GlobeNewswire

    InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine

    The Lancet Respiratory Medicine, a peer-reviewed journal, published the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III studies conducted in invasively mechanically ventilated, critically ill COVID-19 patientsIn-depth statistical analysis confirms robustness of clinical survival benefit of vilobelimab treatment on 28-day and 60-day all-cause mortalityVilobelimab targets the inflammatory immune response evoked by SARS-CoV-2 infection that caus